Search

AMP

Actualités Médicales & Pharmaceutiques

Category

English

AMP | Antibiotic resistance !

Key facts

 

  • Antibiotic resistance is one of the biggest threats to global health today. It can affect anyone, of any age, in any country.
  • Antibiotic resistance occurs naturally, but misuse of antibiotics in humans and animals is accelerating the process.
  • A growing number of infections—such as pneumonia, tuberculosis, and gonorrhoea—are becoming harder to treat as the antibiotics used to treat them become less effective.
  • Antibiotic resistance leads to longer hospital stays, higher medical costs and increased mortality

Continue reading “AMP | Antibiotic resistance !”

FDA Approves Ocaliva ..

FDA Grants Accelerated Approval to Ocaliva (obeticholic acid) for Primary Biliary Cholangitis ..

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis, previously known as primary biliary cirrhosis (PBC), in combination with ursodeoxycholic acid(UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.

Continue reading “FDA Approves Ocaliva ..”

FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer

The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients. Such mutations are present in approximately 10-20 percent of non-small cell lung cancers (NSCLC). Lung cancer is the leading cause of cancer-related death among men and women in the U.S. and, though more common in men, the number of deaths from lung cancer in women is increasing.

Continue reading “FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer”

AspireAssist : How It Works

This video demonstrates a new minimally-invasive method for weight loss ..

Aspirin Often Wrongly Prescribed for Atrial Fibrillation

More than one-third of U.S. patients with the abnormal heartbeat atrial fibrillation who need a blood thinner to prevent strokes aren’t getting one, researchers say.

About 40 percent of “a-fib” patients deemed at moderate to severe risk of stroke because of age or other conditions are prescribed aspirin alone rather than recommended blood thinners such as Xarelto (rivaroxaban) or warfarin, according to a new study.

Continue reading “Aspirin Often Wrongly Prescribed for Atrial Fibrillation”

Experimental Genital Herpes Drug Shows Promise

An experimental immune-boosting treatment for genital herpes shows promise, researchers report.

The drug, called GEN-003, may reduce both virus activity and the number of days with recurrent herpes in patients. The treatment is given in a series of three injections and appears to last for up to one year, the investigators said.

Continue reading “Experimental Genital Herpes Drug Shows Promise”

AMP : FDA Approves Probuphine (buprenorphine) Implant for Treatment of Opioid Dependence

May 26, 2016 — The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.

Until today, buprenorphine for the treatment of opioid dependence was only approved as a pill or a film placed under the tongue or on the inside of a person’s cheek until it dissolved. While effective, a pill or film may be lost, forgotten or stolen.

Continue reading “AMP : FDA Approves Probuphine (buprenorphine) Implant for Treatment of Opioid Dependence”

AMP : FDA Approves Zinbryta

Food and Drug Administration today approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis (MS). Zinbryta is a long-acting injection that is self- administered by the patient monthly.

“Zinbryta provides an additional choice to patients who may require a new option for treatment,” said Billy Dunn, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. Continue reading “AMP : FDA Approves Zinbryta”

AMP : A New Antibiotic to the Rescue?

An experimental antibiotic has shown promise against a dangerous drug-resistant bacteria in animals, researchers report.

A combination of the new antibiotic TXA709 and the antibiotic cefdinir successfully treated animals infected with the so-called “superbug” MRSA — methicillin-resistant staphylococcus aureus.

Continue reading “AMP : A New Antibiotic to the Rescue?”

Blog at WordPress.com.

Up ↑